Loading...
01/11 11:26
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed sentiment. Positive aspects include strong revenue growth for YorvaPath and collaboration with Novo Nordisk. However, there are concerns about rising operating expenses and supply chain challenges. The Q&A reveals uncertainties in reimbursement and lack of clarity in some responses, leading to a cautious market sentiment. No shareholder return plan was announced, which might disappoint investors. The overall sentiment is neutral, with no major negative or positive catalysts to significantly impact the stock price.
YORVIPATH Revenue €44.7 million, up from €13.6 million in Q4 2024, driven by strong U.S. launch and steady growth outside the U.S.
SKYTROFA Revenue €51.3 million, stable pricing and market share, but impacted by seasonal items including reduction in channel inventory and higher copay assistance.
Total Revenue €101 million, includes non-product revenue from collaboration partners.
R&D Costs €86.6 million, up from €70.7 million in Q1 2024, with the previous year including a favorable €10.6 million reversal of prior period write downs.
SG&A Expenses €101 million, up from €66.8 million in Q1 2024, primarily driven by global commercial expansion.
Total Operating Expenses €188 million for Q1 2025.
Non-Cash Gain from Visen IPO €33.6 million recognized as part of share of profit loss of associates.
Net Finance Expenses €15.9 million, driven primarily by non-cash items.
Net Cash Financial Income €3.3 million for Q1 2025.
Cash and Cash Equivalents €518 million, down from €560 million as of December 31, 2024.
YORVIPATH Revenue: First quarter total global YORVIPATH revenue grew to €45 million compared to €40 million in the fourth quarter of last year.
SKYTROFA Revenue: Q1 revenues for SKYTROFA were €51 million, with continued patient growth and global expansion.
TransCon CNP Development: TransCon CNP is set to become the second pillar in our growth disorder strategy, with an NDA submitted to FDA in March and an MAA expected in Q3.
YORVIPATH U.S. Launch: YORVIPATH was prescribed in the U.S. by more than 1,000 unique prescribers for more than 1,750 patients.
SKYTROFA Market Share: We have around 7% market share of the total growth hormone market in the U.S. and around 43% of the total U.S. long acting growth hormone market.
R&D Costs: R&D costs totaled €86.6 million compared to €70.7 million during the first quarter of 2024.
SG&A Expenses: SG&A expenses in the first quarter of 2025 totaled €101 million compared to €66.8 million during the first quarter of 2024.
Regulatory Submissions: We submitted an NDA to FDA for TransCon CNP in March and plan to submit an MAA during Q3.
Combination Therapy Trial: We are conducting the COACH Trial, the first Phase 2 study combining CNP and growth hormone in achondroplasia.
Regulatory Risks: The company faces risks related to ongoing and planned regulatory filings, including the potential for delays or unfavorable outcomes in regulatory decisions for their product candidates.
Market Competition: Ascendis Pharma operates in a competitive biopharma landscape, particularly in the growth hormone market, where they must maintain their market share against established competitors.
Supply Chain Challenges: The company may encounter supply chain challenges that could impact the availability and distribution of their products, particularly as they expand their market presence.
Economic Factors: Fluctuations in currency exchange rates, particularly the Euro-dollar exchange rate, could affect reported revenue and overall financial performance.
Financial Performance: The company reported significant increases in operating expenses, which could impact profitability if revenue growth does not keep pace.
Patient Access and Reimbursement: The success of YORVIPATH's launch is contingent on patient access and reimbursement dynamics, which can vary significantly across different markets.
YORVIPATH Launch: Ascendis Pharma reported a strong U.S. launch of YORVIPATH, with over 1,750 patients prescribed by more than 1,000 unique prescribers. The company expects YORVIPATH to significantly contribute to revenue in 2025.
SKYTROFA Positioning: SKYTROFA is established as a high-value brand in the growth hormone market, with plans for label expansion and a basket trial for various indications.
TransCon CNP Development: TransCon CNP is in pivotal trials and is expected to be a key product for treating achondroplasia, with NDA submitted to the FDA and MAA planned for Q3 2025.
COACH Trial: Ascendis is conducting the COACH Trial, a Phase 2 study combining CNP and growth hormone for achondroplasia, with results expected this quarter.
Vision 2030: Ascendis aims to create value in various therapeutic areas through innovative business models and collaborations, including with Novo Nordisk.
2025 Revenue Growth: Ascendis expects substantial revenue growth driven by YORVIPATH and continued contributions from SKYTROFA, but is not providing specific revenue guidance at this time.
Financial Outlook: The company anticipates that YORVIPATH will have a substantial impact on its financial profile in 2025, with steady revenue growth expected both inside and outside the U.S.
Cash Position: Ascendis ended Q1 2025 with cash and cash equivalents totaling €518 million.
Operating Expenses: Total operating expenses for Q1 2025 were €188 million, with R&D costs at €86.6 million and SG&A expenses at €101 million.
Shareholder Return Plan: Ascendis Pharma has not announced any share buyback program or dividend program during the Q1 2025 earnings call.
The earnings call presents a strong financial performance with expected revenue growth from YORVIPATH and SKYTROFA, supported by label expansions and global launches. The company anticipates becoming cash flow positive, which is a positive indicator. The Q&A section highlights confidence in overcoming challenges, with high patient retention rates and strategic market penetration. The overall sentiment is positive, supported by optimistic guidance and strategic growth plans, likely leading to a stock price increase in the short term.
The earnings call reveals a strong financial performance with significant revenue growth and a successful launch of YORVIPATH. Despite increased SG&A expenses due to global expansion, the company shows a positive outlook with steady patient enrollment and high compliance rates. The Q&A section highlighted management's efforts to improve processes and their optimistic view of market potential. Although some guidance was not provided, the overall sentiment is positive, suggesting a potential stock price increase of 2% to 8% over the next two weeks.
Despite strong revenue growth and a new partnership with Novo Nordisk, the earnings miss, high operating expenses, and vague management responses in the Q&A session create uncertainty. The lack of clear guidance on reimbursement and revenue split, alongside cash flow concerns, offset the positive impact of the partnership and product launches. The neutral shareholder return plan further contributes to a neutral sentiment.
The earnings call presents a mixed sentiment. Positive aspects include strong revenue growth for YorvaPath and collaboration with Novo Nordisk. However, there are concerns about rising operating expenses and supply chain challenges. The Q&A reveals uncertainties in reimbursement and lack of clarity in some responses, leading to a cautious market sentiment. No shareholder return plan was announced, which might disappoint investors. The overall sentiment is neutral, with no major negative or positive catalysts to significantly impact the stock price.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
